Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market Global Report 2026

The messenger ribonucleic acid (mRNA) combination vaccine market size has grown rapidly in recent years. It will grow from $13.18 billion in 2025 to $15.67 billion in 2026 at a compound annual growth rate (CAGR) of 18.9%. The growth in the historic period can be attributed to increasing prevalence of respiratory infections, growth in government immunization initiatives, rising adoption of mRNA vaccine technology, expansion of pandemic preparedness programs, increasing investments in vaccine research and development.

The messenger ribonucleic acid (mRNA) combination vaccine market size is expected to see rapid growth in the next few years. It will grow to $31.57 billion in 2030 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to advancement in multi-pathogen vaccine platforms, increasing demand for convenient vaccination schedules, growth in personalized vaccine development, rising focus on elderly and immunocompromised populations, expansion of global vaccine accessibility programs. Major trends in the forecast period include development of pan-respiratory vaccine platforms, increasing focus on single-dose combination immunization, rising demand for age-specific vaccine formulations, expansion of next-generation multi-pathogen vaccine development, increasing investments in broad-spectrum respiratory disease prevention.

The rising burden of respiratory diseases is expected to propel the growth of the messenger ribonucleic acid (mRNA) combination vaccine market going forward. Respiratory diseases are infectious conditions that affect the lungs and respiratory tract, including influenza, COVID-19, and respiratory syncytial virus (RSV), and they create significant healthcare and economic burdens worldwide. The burden of respiratory diseases is increasing due to the continued spread of seasonal and viral respiratory infections across aging and high-risk populations. The messenger ribonucleic acid (mRNA) combination vaccine helps in respiratory disease prevention by enabling protection against multiple respiratory viruses through a single immunization, improving vaccination efficiency and public health coverage. For instance, in November 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, the 2023-2024 influenza season caused approximately 40 million illnesses, 470,000 hospitalizations, and 28,000 deaths in the United States, compared to the previous 2022-2023 season, reflecting increases of around 29% in illnesses, 30.6% in hospitalizations, and 33.3% in deaths. Therefore, the rising burden of respiratory diseases is driving the growth of the messenger ribonucleic acid (mRNA) combination vaccine market.

Major companies operating in the messenger ribonucleic acid (mRNA) combination vaccine market are focusing on developing advanced multivalent vaccine solutions, such as dual-target mRNA vaccines, to enhance immunization efficiency, improve protection against multiple respiratory diseases, and simplify annual vaccination programs. Dual-target mRNA vaccines refer to vaccines that use messenger RNA technology to simultaneously target and generate immune protection against two distinct diseases, pathogens, or antigens within a single formulation. For instance, in April 2026, Moderna, a US-based biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines, received European Commission marketing authorization for mCOMBRIAX, the world’s first approved mRNA combination vaccine targeting both seasonal influenza and COVID-19 in a single shot. Authorized for adults aged 50 years and older, the vaccine is designed to simplify annual respiratory immunization programs, improve vaccination coverage, and provide enhanced protection against multiple circulating respiratory viruses through Moderna’s mRNA platform.

In December 2025, BioNTech SE, a Germany-based biotechnology company, acquired CureVac N.V. for $1.25 billion. Through this acquisition, BioNTech SE aimed to strengthen its mRNA platform technologies and expand its capabilities in developing combination vaccines for COVID-19 and influenza. CureVac N.V. is a Germany-based biotechnology company specializing in mRNA therapeutics and combination respiratory vaccine development.

Major companies operating in the messenger ribonucleic acid (mrna) combination vaccine market are Moderna Inc.; Pfizer Inc.; BioNTech SE; Sanofi S.A.; GSK; CSL Limited; Arcturus Therapeutics Holdings Inc.; CureVac; Merck & Co.; Daiichi Sankyo; CSPC Pharmaceutical Group Limited; Walvax Biotechnology Co. Ltd.; Translate Bio (Sanofi); Gritstone bio Inc.; HDT Bio Corp.; Gennova Biopharmaceuticals Limited; Ethris GmbH; eTheRNA immunotherapies NV; Providence Therapeutics Holdings Inc.; Abogen Biosciences Co. Ltd.; Immorna Biotherapeutics Inc.; Replicate Bioscience Inc.; PopVax Inc.; GeneOne Life Science Inc.

North America was the largest region in the messenger ribonucleic acid (mRNA) combination vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribonucleic acid (mRNA) combination vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the messenger ribonucleic acid (mRNA) combination vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The messenger ribonucleic acid (mRNA) combination vaccine market consists of sales of multivalent respiratory vaccines, personalized cancer mRNA vaccines, lipid nanoparticle (LNP) vaccine formulations, and related booster vaccine products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The messenger ribonucleic acid (mrna) combination vaccine market research report is one of a series of new reports that provides messenger ribonucleic acid (mrna) combination vaccine market statistics, including messenger ribonucleic acid (mrna) combination vaccine industry global market size, regional shares, competitors with a messenger ribonucleic acid (mrna) combination vaccine market share, detailed messenger ribonucleic acid (mrna) combination vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mrna) combination vaccine industry. This messenger ribonucleic acid (mrna) combination vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.